Actos Damages Slashed But Takeda, Lilly Vow To Fight On
This article was originally published in PharmAsia News
Executive Summary
A massive reduction in the amount of punitive damages awarded against Takeda and Lilly in an ongoing U.S. legal case concerning the bladder cancer risks of diabetes drug Actos is still not enough to satisfy the companies.